Clinical Trial

A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.
Protocol Amendment History 2 changes
critical Trial completed 2026-05-29
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-15
Trial Details
NCT Number NCT07232589
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 26 participants
Start Date 2025-12-08
Primary Completion 2026-05-04 (estimated)
Study Completion 2026-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-29